HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Industry Roundup: DXM Bill Moves, CHPA Biz Dev VP, Neurobrands Injunction

This article was originally published in The Tan Sheet

Executive Summary

House subcommittee approves DXM Abuse bill; UK ire for US firm’s patch claims; Innophos VP hire; and more news in brief.

You may also be interested in...



Tiger Balm External Analgesic Firm Scratched Again On US GMP Violations

Inspection in February and March found GMP violations including failing to thoroughly investigate unexplained batch discrepancies or failures, regardless of whether it already is distributed, are repeats from 2010 problems FDA found at Haw Par Healthcare.

OTC Device Claims For COPD ‘Therapy’ Put Patients At Risk – UK Regulator

ASA finds device marketer BioLife Solutions could not rely on a disclaimer and use of the word “therapy” instead of “treatment” to offset the message its Airnergy device treats a medical condition. ASA advices not to make COPD treatment claims unless a product is properly certified.

OTC Device Claims For COPD ‘Therapy’ Put Patients At Risk – UK Regulator

ASA finds device marketer BioLife Solutions could not rely on a disclaimer and use of the word “therapy” instead of “treatment” to offset the message its Airnergy device treats a medical condition. ASA advices not to make COPD treatment claims unless a product is properly certified.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

RS108879

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel